Alectinib tops crizotinib for advanced ALK+ NSCLC

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Alectinib (Alecensa, Chugai Pharmaceutical and F. Hoffmann-La Roche) offers better outcomes and lower toxicity as a first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive NSCLC than crizotinib (Xalkori, Pfizer).

Why this matters

  • Although crizotinib is s...